Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1455-1460

  Niyazi, Maximilian ^a   Marini, Patrizia ^a   Daniel, Peter T ^b   Humphreys, Robin ^c   Jendrossek, Verena ^d   Belka, Claus ^e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c GLAXOSMITHKLINE   (United States)

^d Department of Molecular Cell Biology ^*  (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cisplatin; Lexatumumab; Mapatumumab; Radiotherapy; TRAIL antibodies; Triple therapy

Indexed keywords

CISPLATIN; LEXATUMUMAB; MAPATUMUMAB; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN BAX; TNFRSF10A PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL STRAIN HCT116; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; RADIATION EXPOSURE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS, SQUAMOUS CELL; RADIOTHERAPY, ADJUVANT; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 67649935020     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000374     Document Type: Article

References (31)

1. Vokes EE, Crawford J, Bogart J, Socinski MA, Clamon G and Green MR: Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 11: S5045-S5050, 2005.
2. Fietkau R: Concomitant radiochemotherapy of advanced nonsmall-cell lung cancer. Lung Cancer 33 (Suppl. 1): S65-S76, 2001.
3. Rodel C and Sauer R: Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 13: 93-101, 2004.
4. Carcaterrra M, Osti MF, De Sanctis V, Caruso C, Berardi F and Enrici RM: Adjuvant radiotherapy and radiochemotherapy in the management of esophageal cancer: a review of the literature. Rays 30: 319-322, 2005.
5. Belkacemi Y, Berger C, Poortmans P, et al: Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 56: 1274-1283, 2003.
6. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, et al: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 61: 1136-1142, 2005.
7. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355: 949-955, 2000.
8. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxiainducible factor 1alpha expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000.
9. Komaki R, Liao Z and Milas L: Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol 31: 47-53, 2004.
10. Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M and Belka C: Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. Radiat Oncol 1: 9, 2006
11. Baumann M, Krause M, Zips D, et al: Molecular targeting in radiotherapy of lung cancer. Lung Cancer 45 (Suppl. 2): S187-S197, 2004.
12. Pajonk F, Pajonk K and McBride WH: Inhibition of NFkappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 91: 1956-1960, 1999.
13. Cengel KA and McKenna WG: Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model. Crit Rev Oncol Hematol 55: 103-116, 2005.
14. Gupta AK, Cerniglia GJ, Mick R, McKenna WG and Muschel RJ: HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 65: 8256-8265, 2005.
15. Rodel C and Sauer R: Integration of novel agents into combinedmodality treatment for rectal cancer patients. Strahlenther Onkol 183: 227-235, 2007.
16. Marini P, Denzinger S, Schiller D, et al: Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145-5154, 2006.
17. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996.
18. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
19. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
20. Marini P and Belka C: Death receptor ligands: new strategies for combined treatment with ionizing radiation. Curr Med Chem Anticancer Agents 3: 334-342, 2003.
21. Brizel DM and Esclamado R: Concurrent chemoradiotherapy for locally advanced, non-metastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol 24: 2612-2617, 2006.
22. Pfister DG, Su YB, Kraus DH, et al: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for loco-regionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072-1078, 2006.
23. Candelaria M, Garcia-Arias A, Cetina L and Duenas-Gonzalez A: Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 1: 15, 2006.
24. Straughn JM, Oliver PG, Zhou T, et al: Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 101: 46-54, 2006.
25. Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, Giaccone G and Kruyt FA: Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. Br J Cancer 91: 171-177, 2004.
26. Buchsbaum DJ, Zhou T, Grizzle WE, et al: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9: 3731-3741, 2003.
27. Niyazi M and Belka C: Isobologram analysis of triple therapies. Radiat Oncol 1: 39, 2006.
28. Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science 29: 989-992, 2000.
29. Brown JM and Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399, 1999.
30. Belka C and Budach W: Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. Int J Radiat Biol 78: 643-658, 2002.
31. Rubel A, Handrick R, Lindner LH, et al: The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol 1: 6, 2006.